Patricia Di Ciano, Sampson Zhao, Pamela Kaduri, Siddhi Patel, Kruti Bhakta, Christine M Wickens, Sheng Chen, Bernard Le Foll, Bruna Brands
{"title":"Effects of naturalistic doses of cannabis edibles on cognition and association with blood THC.","authors":"Patricia Di Ciano, Sampson Zhao, Pamela Kaduri, Siddhi Patel, Kruti Bhakta, Christine M Wickens, Sheng Chen, Bernard Le Foll, Bruna Brands","doi":"10.1007/s00213-025-06863-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Smoked cannabis is known to have effects on cognitive function. The use of edibles is on the rise yet there are few studies of the effects of edibles on cognitive function. Further, most studies of cannabis used fixed laboratory doses which may not capture some of the nuances of more naturalistic doses. Delta-9-tetrahydrocannabinol (THC) is the psychoactive component of cannabis yet the relationship of blood THC to cognitive performance is unclear.</p><p><strong>Methods: </strong>In the present observational study participants (n = 22) were invited to the lab to use their regular legally sourced cannabis edibles. At 150 and 270 min after ingesting the edible, measures of learning and memory (verbal free recall task), executive function (trail making test) and functional vision and visual attention (useful field of view test) were taken. Subjective experiences were also measured, and blood THC was correlated with cognitive outcomes.</p><p><strong>Results: </strong>At 150 min after taking a cannabis edible (mean 7.3 ± 2.9 mg of delta-9-tetrahydrocannabinol) decreases were seen in performance on two measures of the verbal free recall. No effects were found on the useful field of view and trail making tests. There were significant increases in subjective experiences as assessed with a visual analog scale and the Addiction Research Centre Inventory; some changes were also seen on the Profile of Mood States. Blood THC was not correlated with any cognitive outcomes.</p><p><strong>Conclusions: </strong>In sum, the present results suggest that people who choose to use relatively low doses of cannabis edibles may experience decrements in cognitive function while experiencing intoxication.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06863-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Smoked cannabis is known to have effects on cognitive function. The use of edibles is on the rise yet there are few studies of the effects of edibles on cognitive function. Further, most studies of cannabis used fixed laboratory doses which may not capture some of the nuances of more naturalistic doses. Delta-9-tetrahydrocannabinol (THC) is the psychoactive component of cannabis yet the relationship of blood THC to cognitive performance is unclear.
Methods: In the present observational study participants (n = 22) were invited to the lab to use their regular legally sourced cannabis edibles. At 150 and 270 min after ingesting the edible, measures of learning and memory (verbal free recall task), executive function (trail making test) and functional vision and visual attention (useful field of view test) were taken. Subjective experiences were also measured, and blood THC was correlated with cognitive outcomes.
Results: At 150 min after taking a cannabis edible (mean 7.3 ± 2.9 mg of delta-9-tetrahydrocannabinol) decreases were seen in performance on two measures of the verbal free recall. No effects were found on the useful field of view and trail making tests. There were significant increases in subjective experiences as assessed with a visual analog scale and the Addiction Research Centre Inventory; some changes were also seen on the Profile of Mood States. Blood THC was not correlated with any cognitive outcomes.
Conclusions: In sum, the present results suggest that people who choose to use relatively low doses of cannabis edibles may experience decrements in cognitive function while experiencing intoxication.
期刊介绍：
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
